Frank Chen, MD
Psychiatry · Houston, TXNPI 1932294584
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $798,683 of the $940,723 with a category attached, or 84.9%. 22 manufacturers reported payments, led by Alkermes, Inc. at 39.2% of the total. 2025 is the largest year on record at $359,008, 3.0 times the $121,134 reported in 2019. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,173 payments — averaging $801.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$369K
- Teva Pharmaceuticals USA, Inc.$250K
- Otsuka America Pharmaceutical, Inc.$174K
- E.r. Squibb & Sons, L.L.C.$113K
- Luye Pharma (USA) Ltd.$18K
- Eli Lilly$7K
- plus $8K from 16 others
What the payments were for
- Consulting fees$50,1295%
- Speaking & faculty fees$798,68385%
- Travel & lodging$64,5167%
- Food & beverage$27,2913%
- Education$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 490 | $369,076 |
| Teva Pharmaceuticals USA, Inc. | 239 | $249,961 |
| Otsuka America Pharmaceutical, Inc. | 219 | $174,172 |
| E.r. Squibb & Sons, L.L.C. | 132 | $113,332 |
| Luye Pharma (USA) Ltd. | 20 | $18,463 |
| Eli Lilly | 2 | $7,300 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 18 | $7,243 |
| AbbVie(2 entities) | 16 | $417 |
| Johnson & Johnson | 12 | $239 |
| Axsome Therapeutics, Inc. | 5 | $105 |
| Indivior Inc. | 4 | $84 |
| Lundbeck LLC | 4 | $74 |
| Janssen Scientific Affairs, LLC | 2 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Tris Pharma Inc | 1 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Corium, LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Bausch Health US, LLC | 1 | $15 |
| Biogen | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$757,552
- LYBALVI$696,740
- UZEDY$243,408
- ARISTADA INITIO$180,061
- ABILIFY MAINTENA$115,637
- COBENFY$108,783
- ABILIFY ASIMTUFII$84,938
- ABILIFY MYCITE$63,109
- ERZOFRI EXTENDED-RELEASE$18,396
- VRAYLAR$128
- REJOYN$107
How this compares
$940,723 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 20 | $61,894 |
| Lisdexamfetamine Dimesylate | 13 | $2,021 |
| Clonazepam | 128 | $1,958 |
| Paliperidone ErPaliperidone | 16 | $1,939 |
| Quetiapine Fumarate | 89 | $1,615 |
| Aripiprazole | 28 | $1,612 |
| Zolpidem Tartrate ErZolpidem Tartrate | 13 | $1,241 |
| Divalproex Sodium ErDivalproex Sodium | 36 | $1,108 |
| Bupropion XlBupropion Hcl | 20 | $910 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 33 | $848 |
| Haloperidol | 13 | $618 |
| Methylphenidate ErMethylphenidate Hcl | 13 | $558 |
| Trazodone Hcl | 66 | $519 |
| Mirtazapine | 26 | $433 |
| Olanzapine | 22 | $411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada | $369,076 | $61,89420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
- Prashant GajwaniHouston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.